Drugs / Carboplatin
last change yesterday re-read 8 days ago

Carboplatin

Small molecule

Developed for
non-small cell lung carcinoma · breast cancer · ovarian cancer · lung cancer · small cell lung carcinoma · triple-negative breast carcinoma · head and neck squamous cell carcinoma · ovarian carcinoma
+478 more · primary peritoneal carcinoma · fallopian tube cancer · esophageal squamous cell carcinoma · neuroblastoma · cancer · cervical cancer · esophageal cancer · endometrial cancer · female breast carcinoma · head and neck cancer · central nervous system neoplasm · cancer of unknown primary site · fallopian tube carcinoma · HER2 positive breast carcinoma · peritoneum cancer · retinoblastoma · prostate cancer · neoplasm · urothelial carcinoma · lung adenocarcinoma · malignant epithelial tumor of ovary · castration-resistant prostate carcinoma · lymphoma · extragonadal germ cell tumor · testicular germ cell tumor · urinary bladder cancer · gastric cancer · oropharynx squamous cell carcinoma · squamous cell carcinoma · metastatic prostate carcinoma · ovarian neoplasm · gastroesophageal junction adenocarcinoma · ovarian endometrioid adenocarcinoma · peritoneal carcinoma · sarcoma · colorectal cancer · lung carcinoma · oral cavity squamous cell carcinoma · brain neoplasm · childhood germ cell tumor · glioblastoma · hypopharynx squamous cell carcinoma · medulloblastoma · metastatic malignant neoplasm in the brain · metastatic neoplasm · ovarian serous adenocarcinoma · undifferentiated ovarian carcinoma · childhood malignant neoplasm · esophageal adenocarcinoma · melanoma · metastatic malignant neoplasm · kidney cancer · laryngeal squamous cell carcinoma · leukemia · myelodysplastic syndrome · ovarian serous cystadenocarcinoma · pancreatic ductal adenocarcinoma · cervical carcinoma · endometrial clear cell adenocarcinoma · fallopian tube serous adenocarcinoma · lung large cell carcinoma · non-Hodgkin lymphoma · ovarian clear cell adenocarcinoma · ovarian clear cell cystadenocarcinoma · ovarian mucinous cystadenocarcinoma · peritoneal neoplasm · primary peritoneal serous adenocarcinoma · renal pelvis/ureter urothelial carcinoma · adenosquamous lung carcinoma · brain cancer · BRCA1-related cancer predisposition · BRCA2-related cancer predisposition · breast neoplasm · endometrial serous adenocarcinoma · fallopian tube clear cell adenocarcinoma · fallopian tube endometrioid adenocarcinoma · fallopian tube neoplasm · germ cell tumor · Hodgkins lymphoma · hormone receptor-positive breast cancer · intraocular retinoblastoma · liver cancer · mesothelioma · non-small cell squamous lung carcinoma · soft tissue sarcoma · urethra cancer · uterine adnexa cancer · Burkitt lymphoma · colorectal neoplasm · cutaneous melanoma · diffuse large B-cell lymphoma · endometrium neoplasm · fallopian tube mucinous adenocarcinoma · fallopian tube transitional cell carcinoma · gastroesophageal cancer · hepatoblastoma · Her2-receptor negative breast cancer · human papillomavirus-related squamous cell carcinoma · invasive breast carcinoma · lung neoplasm · malignant pleural mesothelioma · nasal cavity and paranasal sinus squamous cell carcinoma · neoplastic disease or syndrome · oropharynx cancer · ovarian carcinosarcoma · ovarian transitional cell carcinoma · prostate adenocarcinoma · seminoma · squamous cell lung carcinoma · teratoma · bladder transitional cell carcinoma · breast carcinoma · carcinosarcoma · central nervous system cancer · cervical adenosquamous carcinoma · chronic lymphocytic leukemia/small lymphocytic lymphoma · classic Hodgkin lymphoma · cutaneous neuroendocrine carcinoma · endometrial carcinoma · inflammatory breast carcinoma · large-cell immunoblastic lymphoma · larynx verrucous carcinoma · male breast carcinoma · mantle cell lymphoma · myeloproliferative neoplasm · nasopharyngeal carcinoma · neuroendocrine carcinoma · ovarian Brenner tumor · ovarian seromucinous carcinoma · peripheral T-cell lymphoma, not otherwise specified · refractory malignant neoplasm · thymic carcinoma · uterine cancer · uterine corpus cancer · uterine corpus sarcoma · adenocarcinoma · anaplastic astrocytoma · anaplastic large cell lymphoma · anaplastic oligodendroglioma · atypical teratoid rhabdoid tumor · B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma · Brenner tumor · bronchogenic carcinoma · central nervous system germ cell tumor · cholangiocarcinoma · chronic myelomonocytic leukemia · digestive system neuroendocrine neoplasm · endometrium adenocarcinoma · ependymoma · estrogen-receptor positive breast cancer · Ewing sarcoma · extranodal nasal NK/T cell lymphoma · gastroesophageal adenocarcinoma · grade III lymphomatoid granulomatosis · head and neck neoplasm · hereditary breast ovarian cancer syndrome · hormone-resistant prostate carcinoma · malignant glioma · MALT lymphoma · metastatic squamous cell carcinoma · nasopharyngeal squamous cell carcinoma · neuroendocrine neoplasm · nodal marginal zone B-cell lymphoma · oral cavity cancer · oropharyngeal carcinoma · ovarian germ cell tumor · ovarian mucinous adenocarcinoma · pancreatic neoplasm · plasma cell neoplasm · primary mediastinal large B-cell lymphoma · prostate carcinoma · prostate small cell carcinoma · salivary gland squamous cell carcinoma · serous adenocarcinoma · sinonasal undifferentiated carcinoma · small intestine cancer · splenic marginal zone lymphoma · supratentorial primitive neuroectodermal tumor · testicular cancer · urinary bladder neoplasm · uterine carcinosarcoma · verrucous carcinoma of oral cavity · vulva cancer · vulvar squamous cell carcinoma · Waldenstrom macroglobulinemia · acute megakaryoblastic leukemia in adult · acute myeloblastic leukemia with maturation · acute myeloblastic leukemia without maturation · acute myeloid leukemia · acute myeloid leukemia with 11q23 abnormalities · acute myeloid leukemia with minimal differentiation · acute myeloid leukemia with t(8;21)(q22;q22) translocation · acute myeloid leukemia, t(16;16)(p13.1;q22) · acute myelomonocytic leukemia M4 · adult acute lymphoblastic leukemia · adult acute monocytic leukemia · B-cell non-Hodgkin lymphoma · biliary tract cancer · bladder squamous cell carcinoma · breast adenocarcinoma · breast mucinous carcinoma · carcinoma · carcinoma of esophagus · childhood ependymoma · choriocarcinoma · choriocarcinoma of ovary · choriocarcinoma of testis · choroid plexus neoplasm · endometrial adenosquamous carcinoma · endometrial endometrioid adenocarcinoma · esophageal small cell neuroendocrine carcinoma · female reproductive organ cancer · gallbladder cancer · gastrointestinal stromal tumor · glioma · hepatosplenic T-cell lymphoma · high grade malignant neoplasm · IDH-wildtype glioblastoma · infiltrating bladder urothelial carcinoma · intraocular lymphoma · invasive tubular breast carcinoma · kidney Wilms tumor · laryngeal neoplasm · larynx cancer · low grade glioma · malignant epithelial tumor of salivary glands · malignant germ cell tumor · malignant mesothelioma · malignant ovarian Brenner tumor · malignant testicular germ cell tumor · medulloepithelioma · metastatic carcinoma in the bone · metastatic malignant neoplasm in the lymph nodes · metastatic melanoma · mixed germ cell tumor · myelodysplastic/myeloproliferative disease · neoplasm of testis · oral cavity neoplasm · ovarian embryonal carcinoma · ovarian sarcoma · ovarian sex cord-stromal tumor · ovarian yolk sac tumor · pineoblastoma · pleural mesothelioma · precancerous condition · primary brain neoplasm · primitive neuroectodermal tumor · prostate neuroendocrine neoplasm · rhabdomyosarcoma · salivary gland carcinoma · small cell carcinoma · testicular embryonal carcinoma · testicular lymphoma · testicular yolk sac tumor · thymoma · tumor of salivary gland · urinary bladder small cell neuroendocrine carcinoma · uterine cervix neoplasm · yolk sac tumor · acquired polycythemia vera · acute erythroid leukemia · acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) · acute myeloid leukemia, inv(16)(p13.1;q22) · acute myeloid leukemia, KRAS gene mutation · acute myeloid leukemia, t(8;21)(q22; q22.1) · acute myeloid leukemia, t(9;11)(p21.3;q23.3) · adenoid cystic carcinoma · adenosquamous carcinoma · adult glioblastoma · adult T-cell leukemia/lymphoma · aggressive B-cell non-Hodgkin lymphoma · anal canal cancer · anal squamous cell carcinoma · anaplastic ependymoma · anaplastic oligoastrocytoma · anaplastic/large cell medulloblastoma · angioimmunoblastic T-cell lymphoma · anus basaloid carcinoma · anus cancer · atypical choroid plexus papilloma · B-cell childhood acute lymphoblastic leukemia · basaloid squamous cell carcinoma · benign neoplasm · bile duct cancer · bladder mixed adenocarcinoma · brain oligodendroglioma · brainstem neoplasm · carcinoid tumor · carcinoma of pharynx · carcinosarcoma of the corpus uteri · central nervous system germinoma · central nervous system nongerminomatous germ cell tumor · cerebral primitive neuroectodermal tumor · cervical squamous cell carcinoma · cervix disorder · childhood central nervous system germinoma · childhood kidney neoplasm · childhood medulloblastoma · childhood optic nerve glioma · childhood supratentorial embryonal tumor with multilayered rosettes, C19MC-altered · childhood testicular germ cell tumor · choroid plexus carcinoma · chronic myeloid leukemia · clear cell sarcoma of kidney · cloacogenic carcinoma · colon carcinoma · combined thymoma · desmoplastic/nodular medulloblastoma · diffuse astrocytoma · digestive system cancer · ductal breast carcinoma in situ · embryonal carcinoma · embryonal tumor with multilayered rosettes · endocervical adenocarcinoma · endometrioid adenocarcinoma · endometrioid tumor · ependymoblastoma · erythroleukemia · essential thrombocythemia · Ewing sarcoma/peripheral primitive neuroectodermal tumor · extragonadal seminoma · extraocular retinoblastoma · fallopian tube carcinosarcoma · female reproductive system neoplasm · gallbladder carcinoma · ganglioneuroblastoma · gastric adenocarcinoma · gastric cardia adenocarcinoma · germinoma · gestational trophoblastic neoplasm · gliosarcoma · hepatocellular carcinoma · hereditary breast carcinoma · hereditary neoplastic syndrome · high grade B-cell lymphoma · high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement · high-grade B-cell lymphoma double-hit/triple-hit · hypopharyngeal carcinoma · hypopharynx cancer · infiltrating bladder urothelial carcinoma sarcomatoid variant · infiltrating bladder urothelial carcinoma, clear cell variant · infiltrating renal pelvis/ureter urothelial carcinoma · intrahepatic cholangiocarcinoma · iris melanoma · large B-cell lymphoma · leiomyosarcoma · Leydig cell tumor · lip cancer · lung disorder · lung neuroendocrine neoplasm · lung sarcomatoid carcinoma · lung superior sulcus carcinoma · lymphoblastic lymphoma · lymphoepithelioma-like lung carcinoma · major salivary gland cancer · malignant childhood germ cell neoplasm · malignant germ cell tumor of ovary · malignant non-epithelial tumor of ovary · malignant pancreatic neoplasm · malignant peritoneal mesothelioma · malignant sex cord stromal tumor of ovary · malignant teratoma · malignant tumor of neck · medium/large size posterior uveal melanoma · medulloblastoma non-WNT/non-SHH group 3 · medulloblastoma non-WNT/non-SHH group 4 · medulloblastoma SHH activated and TP53 wild-type · medulloblastoma with extensive nodularity · micropapillary variant infiltrating bladder urothelial carcinoma · mixed cell type kidney Wilms' tumor · mixed neoplasm · mixed testicular germ cell cancer · mucosal melanoma · mycosis fungoides and variants · nasal cavity and paranasal sinus carcinoma · nasal cavity cancer · nasopharyngeal type undifferentiated carcinoma · neoplasm of chest wall · neoplasm of esophagus · neoplasm of hypopharynx · neoplasm of oropharynx · nested variant infiltrating bladder urothelial carcinoma · neurofibromatosis type 1 · non-central nervous system-localized embryonal carcinoma · nut midline carcinoma · ocular melanoma with extraocular extension · osteosarcoma · ovarian epithelial tumor · ovarian granulosa cell tumor · ovarian gynandroblastoma · ovarian seromucinous tumor · ovarian serous surface papillary adenocarcinoma · ovarian Sertoli-Leydig cell tumor · pancreas disorder · pancreatic acinar cell carcinoma · pancreatic large cell neuroendocrine carcinoma · paranasal sinus carcinoma · paranasal sinus neoplasm · pediatric ovarian germ cell tumor · pharynx neoplasm · pineal region germinoma · pineal region immature teratoma · pineal region yolk sac tumor · plasmacytoid variant infiltrating bladder urothelial carcinoma · pleural epithelioid mesothelioma · primary central nervous system lymphoma · primary cutaneous B-cell lymphoma · primary cutaneous diffuse large B-cell lymphoma, Leg type · prostate cancer aggressiveness quantitative trait locus on chromosome 19 · prostate neoplasm · pseudomyxoma peritonei · pulmonary large cell neuroendocrine carcinoma · relapsed/refractory diffuse large B-cell lymphoma · renal pelvis neoplasm · reproductive system cancer · RET fusion positive cancer · rhabdoid tumor of the kidney · salivary gland adenoid cystic carcinoma · salivary gland cancer · secondary malignant neoplasm · skin squamous cell carcinoma · small intestine lymphoma · soft tissue neoplasm · squamous cell carcinoma of penis · stage I endometrioid carcinoma · stage II endometrioid carcinoma · T-cell non-Hodgkin lymphoma · T-cell/histiocyte rich large B cell lymphoma · testicular seminoma · thymic epithelial neoplasm · thyroid gland carcinoma · tongue cancer · tongue carcinoma · transitional cell carcinoma · tumor of uterus · undifferentiated carcinoma · undifferentiated high grade pleomorphic sarcoma of bone · unilateral retinoblastoma · ureter neoplasm · ureter small cell carcinoma · ureter transitional cell carcinoma · urethra neoplasm · urinary bladder carcinoma · urinary system neoplasm · uterine carcinoma · vaginal cancer · virus associated tumor · anaplastic ganglioglioma · anaplastic pleomorphic xanthoastrocytoma · angiocentric glioma · breast carcinoma by gene expression profile · central neurocytoma · cerebellar liponeurocytoma · childhood low-grade glioma · childhood oligodendroglioma · chordoid glioma of the third ventricle · desmoplastic infantile astrocytoma/ganglioglioma · diffuse low-grade glioma, MAPK pathway–altered · extraventricular neurocytoma · gangliocytoma · gastric neuroendocrine neoplasm · giant cell glioblastoma · grade II glioma · intestinal neuroendocrine neoplasm · Lhermitte-Duclos disease · lip and oral cavity carcinoma · low-grade astrocytoma · optic pathway glioma · ovarian clear cell cancer · ovarian serous tumor · pancreatic neuroendocrine neoplasm · papillary glioneuronal tumor · pilocytic astrocytoma · pleomorphic xanthoastrocytoma · primary peritoneal serous/papillary carcinoma · renal pelvis carcinoma · rosette-forming glioneuronal tumor of fourth ventricule · ureter cancer
Investigated by
National Cancer Institute (NCI) · Merck Sharp & Dohme LLC · Eli Lilly and Company · AstraZeneca · Genentech, Inc. · M.D. Anderson Cancer Center
+1,008 more · Bristol-Myers Squibb · Memorial Sloan Kettering Cancer Center · Children's Oncology Group · Alliance for Clinical Trials in Oncology · SCRI Development Innovations, LLC · Celgene Corporation · Fudan University · Sun Yat-sen University · Hoffmann-La Roche · Sanofi · Dana-Farber Cancer Institute · GlaxoSmithKline · Gynecologic Oncology Group · Eastern Cooperative Oncology Group · SWOG Cancer Research Network · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · University of Chicago · Children's Cancer and Leukaemia Group · Massachusetts General Hospital · Pfizer · Amgen · European Organisation for Research and Treatment of Cancer - EORTC · Fox Chase Cancer Center · Guangdong Provincial People's Hospital · NRG Oncology · The Netherlands Cancer Institute · Wake Forest University Health Sciences · AbbVie · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Case Comprehensive Cancer Center · UNC Lineberger Comprehensive Cancer Center · Cancer Research UK · City of Hope Medical Center · NYU Langone Health · Shanghai Pulmonary Hospital, Shanghai, China · Washington University School of Medicine · Aventis Pharmaceuticals · Shanghai Chest Hospital · Tianjin Medical University Cancer Institute and Hospital · Fujian Cancer Hospital · Samsung Medical Center · St. Jude Children's Research Hospital · University of Michigan Rogel Cancer Center · Brigham and Women's Hospital · Daiichi Sankyo · Gustave Roussy, Cancer Campus, Grand Paris · H. Lee Moffitt Cancer Center and Research Institute · Hebei Medical University Fourth Hospital · Henan Cancer Hospital · Hunan Cancer Hospital · Jonsson Comprehensive Cancer Center · Masonic Cancer Center, University of Minnesota · National Cancer Institute, Naples · Radiation Therapy Oncology Group · Stanford University · Yonsei University · Zhejiang Cancer Hospital · ARCAGY/ GINECO GROUP · Chinese Academy of Medical Sciences · French Cooperative Thoracic Intergroup · Gilead Sciences · Hellenic Oncology Research Group · Jiangsu Cancer Institute & Hospital · Mayo Clinic · Northwestern University · Ruijin Hospital · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · UNICANCER · University of Washington · Akeso · Centre Leon Berard · GOG Foundation · Huazhong University of Science and Technology · all 1,014 on the full record

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansion US (FDA) PARAPLATIN — 1991-07-05 fda.gov ↗
Approved US (FDA) PARAPLATIN — 1989-03-03 fda.gov ↗

Trials 1,952 · started per year

today
US approved 1989
1
1
2
5
4
2
7
7
17
25
41
43
40
47
37
49
57
65
65
70
73
66
50
50
41
42
49
66
58
59
64
73
82
92
96
86
113
122
76
4
1
19871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030203120322033
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 017 trials
Phase 0 NCT06942039 Sep 2025 → Dec 2030 expected atypical teratoid rhabdoid tumor, childhood medulloblastoma, embryonal tumor with multilayered rosettes, ependymoblastoma +5 C17 Council Recruiting No outcome recorded
Phase 0 NCT07028918 Aug 2025 → Aug 2026 overdue oral cavity squamous cell carcinoma Qilu Hospital of Shandong University Not yet recruiting No outcome recorded
Phase 0 NCT06637306 Mar 2025 → Mar 2027 expected triple-negative breast carcinoma Rima Patel Recruiting No outcome recorded
Phase 0 NCT06204614 Jun 2024 → Jul 2028 expected infiltrating bladder urothelial carcinoma Brigham and Women's Hospital Enrolling by invitation No outcome recorded
Phase 0 NCT06208033 Jan → Oct 2024 non-small cell lung carcinoma Fujian Cancer Hospital Unknown No outcome recorded
Phase 0 NCT05553782 Nov 2023 → Apr 2029 expected head and neck squamous cell carcinoma, salivary gland adenoid cystic carcinoma Brigham and Women's Hospital Recruiting No outcome recorded
Phase 0 NCT05238831 Jan 2023 → May 2026 female breast carcinoma, ovarian carcinoma, pancreatic ductal adenocarcinoma, pancreatic large cell neuroendocrine carcinoma +2 OHSU Knight Cancer Institute Withdrawn No outcome recorded
Phase 0 NCT06062602 Jul 2021 → Nov 2022 head and neck squamous cell carcinoma Presage Biosciences Completed No outcome recorded
Phase 0 NCT04906382 Jul 2021 → Sep 2022 Lynch syndrome, carcinosarcoma of the corpus uteri, endometrial clear cell adenocarcinoma, mismatch repair cancer syndrome Floor Backes, MD Terminated No outcome recorded
Phase 0 NCT04947501 Jun 2021 → Jun 2026 overdue childhood malignant neoplasm, neuroblastoma Memorial Sloan Kettering Cancer Center Active not recruiting No outcome recorded
Phase 1247 trials · 1 met primary · 1 missed
Phase 1 NCT07783659 Feb 2027 → Jun 2030 expected triple-negative breast carcinoma M.D. Anderson Cancer Center Not yet recruiting No outcome recorded
Phase 1 NCT05403723 Jan 2027 → Feb 2028 small cell lung carcinoma University of Maryland, Baltimore Suspended No outcome recorded
Phase 1 NCT07341867 Aug 2026 → Mar 2028 expected plasma cell myeloma, triple-negative breast carcinoma Andrew Hantel, MD Not yet recruiting No outcome recorded
Phase 1 NCT07278336 Nov 2025 → Dec 2028 expected ovarian cancer AbbVie Recruiting No outcome recorded
Phase 1 NCT07178171 Nov 2025 → Aug 2027 expected triple-negative breast carcinoma Xijing Hospital Recruiting No outcome recorded
Phase 1 NCT07090499 Aug 2025 → Jul 2028 expected esophageal adenocarcinoma, esophageal squamous cell carcinoma, gastroesophageal junction adenocarcinoma, head and neck squamous cell carcinoma +4 Pfizer Recruiting No outcome recorded
Phase 1 NCT07046923 Jul 2025 → Jul 2030 expected endometrium neoplasm, metastatic neoplasm, non-small cell lung carcinoma, small cell lung carcinoma +1 Eli Lilly and Company Recruiting No outcome recorded
Phase 1 NCT07317609 Jul 2025 → Sep 2027 expected esophageal squamous cell carcinoma Shanghai Zhongshan Hospital Recruiting No outcome recorded
Phase 1 NCT05733689 Jun 2025 → Jun 2027 expected gastroesophageal adenocarcinoma University of California, Irvine Recruiting No outcome recorded
Phase 1 NCT06946927 Jun 2025 → Feb 2026 overdue non-small cell lung carcinoma Jemincare Recruiting No outcome recorded
Show all 247 trials opens the full record — a long page
Phase 1/2174 trials · 4 met primary · 1 missed
Phase 1/2 NCT07850973 Mar 2027 → Dec 2029 expected malignant germ cell tumor M.D. Anderson Cancer Center Not yet recruiting No outcome recorded
Phase 1/2 NCT07833735 Oct 2026 → Oct 2028 expected cancer CSPC Megalith Biopharmaceutical Co.,Ltd. Not yet recruiting No outcome recorded
Phase 1/2 NCT07843940 Oct 2026 → Apr 2030 expected small cell lung carcinoma Boehringer Ingelheim Not yet recruiting No outcome recorded
Phase 1/2 NCT07559929 Aug 2026 → Jun 2028 expected small cell lung carcinoma Hangzhou DAC Biotechnology Co., Ltd. Recruiting No outcome recorded
Phase 1/2 NCT07623356 Jun 2026 → Jun 2028 expected non-small cell lung carcinoma Akeso Not yet recruiting No outcome recorded
Phase 1/2 NCT07612137 Jun 2026 → Jun 2027 expected cancer Innovent Biologics (Suzhou) Co. Ltd. Not yet recruiting No outcome recorded
Phase 1/2 NCT07453394 Apr 2026 → Apr 2027 expected endometrial cancer, gastric cancer, non-small cell lung carcinoma, ovarian cancer Qilu Pharmaceutical Co., Ltd. Not yet recruiting No outcome recorded
Phase 1/2 NCT07354061 Mar 2026 → Mar 2028 expected non-small cell lung carcinoma Tang-Du Hospital Recruiting No outcome recorded
Phase 1/2 NCT07466160 Feb 2026 → Dec 2027 expected cancer Mabwell (Shanghai) Bioscience Co., Ltd. Recruiting No outcome recorded
Phase 1/2 NCT07397338 Jan 2026 → May 2029 expected colorectal cancer, metastatic neoplasm, non-small cell lung carcinoma Revolution Medicines, Inc. Recruiting No outcome recorded
Show all 174 trials opens the full record — a long page
Phase 21,146 trials · 28 met primary · 44 missed
Phase 2 NCT04832438 Dec 2030 → Jun 2033 adenoid cystic carcinoma, salivary gland carcinoma Actuate Therapeutics Inc. Withdrawn No outcome recorded
Phase 2 NCT07229339 Jun 2027 → Jun 2029 expected non-small cell lung carcinoma Jonsson Comprehensive Cancer Center Not yet recruiting No outcome recorded
Phase 2 NCT07699237 Nov 2026 → Jun 2031 expected small cell lung carcinoma University of Cologne Not yet recruiting No outcome recorded
Phase 2 NCT07857486 Nov 2026 → Feb 2029 expected triple-negative breast carcinoma Institut Paoli-Calmettes Not yet recruiting No outcome recorded
Phase 2 NCT07843303 Oct 2026 → Sep 2028 expected fallopian tube cancer, ovarian carcinoma, primary peritoneal carcinoma Peking University Cancer Hospital & Institute Not yet recruiting No outcome recorded
Phase 2 NCT07845916 Oct 2026 → Jun 2027 expected non-small cell lung carcinoma Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Not yet recruiting No outcome recorded
Phase 2 NCT07811375 Oct 2026 → Mar 2029 expected cervical cancer Anhui Provincial Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07858253 Oct 2026 → Oct 2030 expected lung carcinoma Anusha Chidharla, MD Not yet recruiting No outcome recorded
Phase 2 NCT07807722 Sep 2026 → Mar 2028 expected non-small cell lung carcinoma Hubei Cancer Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07247786 Sep 2026 → Dec 2031 expected non-small cell lung carcinoma Fundación GECP Not yet recruiting No outcome recorded
Show all 1,146 trials opens the full record — a long page
Phase 2/329 trials · 2 met primary · 2 missed
Phase 2/3 NCT07463313 Mar 2026 → Mar 2029 expected combined thymoma Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Not yet recruiting No outcome recorded
Phase 2/3 NCT07005102 Aug 2025 → Nov 2036 expected non-small cell lung carcinoma AbbVie Recruiting No outcome recorded
Phase 2/3 NCT07131319 Apr 2025 → Oct 2028 expected non-small cell lung carcinoma Second Affiliated Hospital of Nanchang University Recruiting No outcome recorded
Phase 2/3 NCT06910072 Apr 2025 → Oct 2026 expected triple-negative breast carcinoma Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting No outcome recorded
Phase 2/3 NCT06211023 Feb 2024 → Jun 2026 ovarian carcinoma Suzhou Suncadia Biopharmaceuticals Co., Ltd. Unknown No outcome recorded
Phase 2/3 NCT06907602 Jan 2024 → Dec 2026 expected esophageal squamous cell carcinoma Peking Union Medical College Hospital Recruiting No outcome recorded
Phase 2/3 NCT05489848 Aug 2022 → Aug 2028 expected endometrial cancer Fudan University Not yet recruiting No outcome recorded
Phase 2/3 NCT05209256 Mar 2022 → Jan 2024 non-small cell lung carcinoma The First Affiliated Hospital of Henan University of Science and Technology Unknown No outcome recorded
Phase 2/3 NCT04681417 Mar 2021 → Jan 2035 expected retinoblastoma Institut Curie Recruiting No outcome recorded
Phase 2/3 NCT04864782 Sep 2020 → Sep 2022 cervical cancer Qilu Pharmaceutical Co., Ltd. Terminated No outcome recorded
Phase 3270 trials · 34 met primary · 46 missed
Phase 3 NCT07715396 Oct 2026 → Oct 2031 expected non-small cell lung carcinoma AIO-Studien-gGmbH Not yet recruiting No outcome recorded
Phase 3 NCT07827872 Oct 2026 → Oct 2032 expected oral cavity squamous cell carcinoma caohaotian Not yet recruiting No outcome recorded
Phase 3 NCT07613567 Sep 2026 → Aug 2032 expected cervical carcinoma Fujian Cancer Hospital Not yet recruiting No outcome recorded
Phase 3 NCT07591467 Sep 2026 → Sep 2036 expected hereditary neoplastic syndrome, prostate cancer, prostate neuroendocrine neoplasm Gustave Roussy, Cancer Campus, Grand Paris Not yet recruiting No outcome recorded
Phase 3 NCT07291102 Jul 2026 → Oct 2034 expected medulloblastoma SHH activated and TP53 wild-type Nationwide Children's Hospital Not yet recruiting No outcome recorded
Phase 3 NCT06914011 May 2026 → Jun 2031 expected esophageal cancer Asan Medical Center Not yet recruiting No outcome recorded
Phase 3 NCT07554846 May 2026 → May 2030 expected — Fudan University Recruiting No outcome recorded
Phase 3 NCT07371611 Jan 2026 → Dec 2030 expected oral cavity squamous cell carcinoma Qunxing Li,MD Recruiting No outcome recorded
Phase 3 NCT07061977 Nov 2025 → Dec 2030 expected cervical adenosquamous carcinoma National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 3 NCT07026474 Oct 2025 → Dec 2032 expected head and neck squamous cell carcinoma Saarland University Recruiting No outcome recorded
Show all 270 trials opens the full record — a long page
Phase 423 trials · 1 met primary
Phase 4 NCT07843251 Oct 2026 → Dec 2030 expected lacrimal apparatus disorder, non-small cell lung carcinoma Anhui Provincial Cancer Hospital Not yet recruiting No outcome recorded
Phase 4 NCT07279935 May 2026 → May 2030 expected non-small cell lung carcinoma AstraZeneca Recruiting No outcome recorded
Phase 4 NCT07093931 Aug 2025 → Aug 2027 expected breast cancer Shandong Cancer Hospital and Institute Not yet recruiting No outcome recorded
Phase 4 NCT06951841 Apr 2025 → May 2026 overdue small cell lung carcinoma China Medical University, China Not yet recruiting No outcome recorded
Phase 4 NCT06485739 Jul 2024 → Jul 2028 expected neuroendocrine neoplasm First Affiliated Hospital Xi'an Jiaotong University Not yet recruiting No outcome recorded
Phase 4 NCT06357598 Jan → Dec 2024 non-small cell lung carcinoma The Affiliated Hospital of Qingdao University Unknown No outcome recorded
Phase 4 NCT05843292 Jul 2023 → Dec 2024 overdue triple-negative breast carcinoma Shanghai Jiao Tong University School of Medicine Not yet recruiting No outcome recorded
Phase 4 NCT04136782 Jul 2021 → Nov 2025 overdue breast cancer Shengjing Hospital Recruiting No outcome recorded
Phase 4 NCT04489888 Oct 2020 → Feb 2023 head and neck squamous cell carcinoma Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 4 NCT03799601 Mar → Dec 2019 non-small cell lung carcinoma Tongji Hospital Unknown No outcome recorded
Phase not applicable46 trials · 1 met primary
— NCT07538193 May 2026 → May 2029 expected metastatic malignant neoplasm in the lymph nodes, non-small cell lung carcinoma Tang-Du Hospital Not yet recruiting No outcome recorded
— NCT07546383 Apr 2026 → Dec 2027 expected head and neck squamous cell carcinoma The Second Affiliated Hospital of Hainan Medical University Recruiting No outcome recorded
— NCT07491822 Mar 2026 → Sep 2027 expected triple-negative breast carcinoma Tianjin Medical University Cancer Institute and Hospital Not yet recruiting No outcome recorded
— NCT07092449 Aug 2025 → Dec 2027 expected gastroesophageal adenocarcinoma, gastroesophageal junction adenocarcinoma Tang-Du Hospital Not yet recruiting No outcome recorded
— NCT06715501 Dec 2024 → Sep 2025 overdue esophageal squamous cell carcinoma First Affiliated Hospital of Ningbo University Enrolling by invitation No outcome recorded
— NCT06363708 Jun 2024 → Dec 2025 endometrium neoplasm Zhongnan Hospital Unknown No outcome recorded
— NCT06420908 May 2024 → May 2026 esophageal squamous cell carcinoma Hebei Medical University Fourth Hospital Withdrawn No outcome recorded Stop: Enrollment
— NCT05921149 May 2024 → Jun 2028 expected chemotherapy-induced toxicity, ovarian cancer Endeavor Health Not yet recruiting No outcome recorded
— NCT05527808 Aug 2022 → Jun 2025 lung adenocarcinoma Jun Liu Unknown No outcome recorded
— NCT05407155 Jun 2022 → Apr 2026 overdue non-small cell lung carcinoma Fudan University Active not recruiting No outcome recorded
Comparator or background therapy1,746 trials
Phase 0 NCT05691010 Background Jan 2023 → Jan 2027 expected endometrial carcinoma Memorial Sloan Kettering Cancer Center Recruiting No outcome recorded
Phase 0 NCT05415709 Background Jun 2022 → Dec 2026 expected fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma, fallopian tube serous adenocarcinoma, ovarian endometrioid adenocarcinoma +3 Ohio State University Comprehensive Cancer Center Recruiting No outcome recorded
Phase 0 NCT03940001 Background May 2019 → May 2021 esophageal squamous cell carcinoma Zhejiang Cancer Hospital Unknown No outcome recorded
Phase 0 NCT03387553 Background Jun 2018 → Aug 2023 HER2 positive breast carcinoma, female breast carcinoma, invasive breast carcinoma, male breast carcinoma H. Lee Moffitt Cancer Center and Research Institute Completed No outcome recorded
Phase 0 NCT00515138 Background May 2007 → Nov 2011 B-cell non-Hodgkin lymphoma University of California, San Francisco Terminated No outcome recorded Stop: Enrollment
Show all 1,746 trials opens the full record — a long page

Press releases naming this drug 44 releases

DateIssuerRelease
2024-06-17 Merck Sharp & Dohme LLC FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma merck.com ↗
2020-09-17 AbbVie ImmunoGen Presents Final Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Avastin® at ESMO abbvie.com ↗
2019-12-04 Hoffmann-La Roche FDA approves Roche’s Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer roche.com ↗
2019-12-03 Genentech, Inc. FDA Approves Genentech’s Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) for The Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer gene.com ↗
2019-09-29 AbbVie ImmunoGen Presents Initial Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination with Carboplatin and Avastin® at ESMO abbvie.com ↗
2019-01-17 Hoffmann-La Roche FDA accepts Roche's supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for initial treatment of metastatic non-squamous non-small cell lung cancer roche.com ↗
2019-01-16 Genentech, Inc. FDA Accepts Genentech’s Supplemental Biologics License Application for Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer gene.com ↗
2019-01-03 Deciphera Pharmaceuticals, LLC Deciphera Pharmaceuticals Initiates a Phase 1b/2 Clinical Trial of Rebastinib in Combination with Carboplatin in Patients with Advanced or Metastatic Solid Tumors deciphera.com ↗
2018-10-30 Merck Sharp & Dohme LLC FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) merck.com ↗
2018-10-22 Hoffmann-La Roche Roche's Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-small cell lung cancer live significantly longer compared to chemotherapy alone roche.com ↗
2018-10-22 Genentech, Inc. Genentech’s Tecentriq Plus Chemotherapy (Carboplatin and Abraxane) as an Initial Treatment Helped People With Advanced Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy Alone gene.com ↗
2018-06-05 Eli Lilly and Company FDA Expands Lilly's ALIMTA® (pemetrexed) Label to Include Combination with KEYTRUDA® (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression lilly.com ↗

Evidence & citations 29 cited values

Every value below carries the sentence it was read from. 3,700 sources stand behind the page.

FieldValueCited text
Known as carboplatin “Option 1: Docetaxel and carboplatin once every 3 weeks for 6 cycles; Option 2: Doxorubicin plus cyclophosphamide once every 3 weeks for 4 cycles, followed by a taxane...” NCT05415215 ↗
3687

“including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE...” NCT04486391 ↗

“Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations: * Carboplatin; * Irinotecan; * Etoposide; *...” NCT03632135 ↗

“Camrelizumab 200 mg (Day 1) intravenous infusion (IV) and Paclitaxel Albumin - bound 125 mg/m² (Day 1, Day 8) IV and Carboplatin AUC 4 (Day 1) IV, with a 21-day cycle for 2...” NCT07432087 ↗

“One or more of the following may be assigned by the physician (physician's choice) per standard of care guidelines upon study enrollment following surgery: Cytarabine,...” NCT06861244 ↗

“We performed a prospective, randomized, phase III, intergroup trial to compare carboplatin plus paclitaxel (TC; area under the curve [AUC] 5 and 175 mg/m(2), respectively) with...” PMID 20733132 ↗ Aug 2010

“Patients received neoadjuvant chemotherapy consisting of paclitaxel (80 mg/m2, day 1 and 8 of each 21-day cycle, intravenous), trastuzumab (6 mg/kg on day 1 of each cycle...” PMID 41713473 ↗ Feb 2026

“After the start of External Beam Radiation Therapy (EBRT), paclitaxel (150-175 mg/m2) or paclitaxel (albumin-bound) 222-260 mg/m2 + cisplatin (60-75 mg/m2) or carboplatin...” NCT06870565 ↗

“Fluorouracil, 1000 mg/m2 per day, intravenously for days 1 to 4; cisplatin, 70 mg/m2 (or carboplatin, area under the curve, 5) intravenously on day 1; and pembrolizumab, 200...” PMID 40965911 ↗ Nov 2025

“Drugs:Chidamide and ICE regimen (ifosfamide, Mesna,Carboplatin and etoposide): Chidamide 20mg on d1,4,8,11;ifosfamide 1.2g/ m2,d1-4,ivg during 4 hours; Mesna 0.4g, 0,4,8 hours...” NCT02856997 ↗

“Pemetrexed (500mg/m2) plus Carboplatin (AUC5)or Pemetrexed (500mg/m2) plus Cisplatin (75mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4\~6 cycles, followed by pemetrexed...” NCT04951648 ↗

Show 3,677 more sources

Known as Car “gemcitabine (Gem) with vinorelbine (Vin), etoposide (Eto), cisplatin (Cis), or carboplatin (Car).” PMID 22031232 ↗ Jan 2012
Known as Carbo “This study will use imaging to look at tumor response to combination chemotherapy of gemcitabine (Gem) and cisplatin (Cis) or gemcitabine and carboplatin (Carbo) in non small...” NCT00599755 ↗
2

“TUB-040 will be administered along with carboplatin (Carbo) and bevacizumab (BEV) as an intravenous (IV) solution on day 1 of each treatment cycle for up to 6 cycles.” NCT07736937 ↗

“Preclinical studies have indicated that arsenic trioxide (ATO) and carboplatin (Carbo) enhance DAC's epigenetic gene derepression.” PMID 40453133 ↗ Jan 2025

Known as Carboplatin (L01XA02) “Carboplatin (L01XA02)” NCT00702975 ↗
Known as Carboplatin (Spectrum Pharmaceuticals, Inc.) “Carboplatin (Spectrum Pharmaceuticals, Inc.)” NCT00695994 ↗
Known as Carboplatin for injection “Carboplatin for injection inhibits DNA synthesis, thereby preventing cancer cell division and reproduction” NCT06897579 ↗
Known as carboplatin for injection or platinum diamine [1,1-cyclobutane-decarbozxylate (2-0,0')-,(SP-4-2)] “carboplatin for injection or platinum diamine [1,1-cyclobutane-decarbozxylate (2-0,0')-,(SP-4-2)]” NCT01107626 ↗
Known as Carboplatin Injection “Carboplatin Injection: Administration and Dosage: Intravenous infusion, AUC=5 mg/ml.min, with a single dose not exceeding 800 mg; Frequency and Duration of Administration: On...” NCT06514027 ↗
5

“CVL006(B006 Injection)、pemetrexed(Pemetrexed Disodium for Injection)、carboplatin(Carboplatin Injection)” NCT07157956 ↗

“Carboplatin injection AUC 5mg/mL/min, intravenous drip, on Day 1 in 21-day cycle.” NCT04439890 ↗

“Cisplatin for Injection / Carboplatin Injection” NCT04568304 ↗

“Paraplatin (Carboplatin Injection) AUC=5 IV.” NCT01820858 ↗

“Drug: Carboplatin Injection” NCT06786312 ↗

Known as Carboplatin Kabi “Drug: carboplatin (Carboplatin Kabi) at a target AUC of 5 mg/mL IV infusion on Day 1 of each 3 week cycle” NCT03562871 ↗
Known as Carboplatin(SANDOZ) “Paclitaxel(Sawai),(NK), Paraplatin(BMS), Carboplatin(SANDOZ)” NCT01506856 ↗
Known as Carboplatin: Carplan “Carboplatin: Carplan” NCT01648517 ↗
Known as Carboplatin: Paraplatin “Carboplatin (Paraplatin®)” NCT02983045 ↗
3

“Carboplatin (Paraplatin)” NCT00675545 ↗

“Carboplatin (Paraplatin)” NCT00856830 ↗

“Carboplatin: Paraplatin” NCT01563601 ↗

Known as Carboplatin: Paraplatin, CBDCA “Carboplatin: Paraplatin, CBDCA” NCT00647426 ↗
Known as Carboplatin: Paraplatin, CBDCA, Paraplatin NovaPlus “Carboplatin: Paraplatin, CBDCA, Paraplatin NovaPlus” NCT00958022 ↗
Known as Carboplatine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00137995 ↗
6

NCT00198354 ↗

NCT02686346 ↗

NCT00864318 ↗

NCT00384826 ↗

NCT07001618 ↗

NCT01857453 ↗

Known as Carboplatinum “Carboplatinum (AUC=5) can be used instead of Cisplatin (75 mg/m2) from cycle 2 for Cisplatin induced neuro/oto/nephrotoxicity as long as the subject remains eligible for...” NCT05500092 ↗
4

NCT04224922 ↗

NCT01969032 ↗

NCT00162695 ↗

NCT01867086 ↗

Known as CBDCA “OBJECTIVES: I. Determine a safe weekly dose of intravenous estramustine (EM) in combination with paclitaxel (TAX) and carboplatin (CBDCA) in patients with advanced prostate cancer.” NCT00003394 ↗
11

“A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)” NCT00936702 ↗

“Paclitaxel plus Carboplatin (TC) therapy; Paclitaxel (PTX) 175 mg/m2 + Carboplatin(CBDCA) area under curve(AUC) 6 q3weeks day1, 3 to 6 cycles” NCT04063527 ↗

“Carboplatin, CBDCA, NSC-241240; or CAP: Cyclophosphamide, CTX, NSC-26271; Doxorubicin, DOX, NSC-123127; Cisplatin, CDDP, NSC-119875.” NCT00002477 ↗

“On days -6 to -4, patients receive etoposide IV over 2 hours and carboplatin (CBDCA) IV over 30 minutes 3 times daily.” NCT00002931 ↗

“Estimate the response rate to adjuvant carboplatin (CBDCA) alone in children with intraocular retinoblastoma.” NCT00002675 ↗

“Assess the response to carboplatin (CBDCA) in patients with progressive low-grade gliomas.” NCT00002749 ↗

“treated with carboplatin (CBDCA) and vincristine (VCR) every 3 weeks for 24 weeks” NCT00002794 ↗

“myeloablative chemotherapy with thiotepa (TSPA) followed by carboplatin (CBDCA)” NCT00002619 ↗

“hyperthermic intraperitoneal chemotherapy using carboplatin (CBDCA)” NCT04415944 ↗

“Carboplatin (CBDCA) and bevacizumab” NCT00626405 ↗

Show 1 more source

Known as CBP “Cisplatin (DDP) or Carboplatin (CBP) plus Albumin-bound Paclitaxel (nab-paclitaxel) are administered according to the protocol.” NCT07791745 ↗
2

“T: paclitaxel (PTX) P: carboplatin (CBP)” NCT03876886 ↗

“CBP(Carboplatin)” NCT05871918 ↗

Known as CBPT “AZD1775 and carboplatin (CBPT)” NCT02937818 ↗
Known as diammine(1,1-cyclobutanedicarboxylato)platinum(II) “Carboplatin \[diammine(1,1-cyclobutanedicarboxylato)platinum(II)\] is one of the most promising second generation platinum compounds.” NCT05438706 ↗
Known as Neoadjuvant chemotherapy (taxol and carboplatin) ClinicalTrials.gov intervention name — accepted as the source's own label NCT00913705 ↗
Known as NSC #214240 “A Dose-Escalating Phase I Study With an Expanded Cohort to Assess the Feasibility of Intraperitoneal Carboplatin (NSC #214240) and Intravenous Paclitaxel (NSC # 673089) and...” NCT00079430 ↗
Known as NSC #241240 “Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or...” NCT00687687 ↗
3

“Carboplatin, CBDCA, NSC-241240; or CAP: Cyclophosphamide, CTX, NSC-26271; Doxorubicin, DOX, NSC-123127; Cisplatin, CDDP, NSC-119875.” NCT00002477 ↗

“cetuximab (C225, NSC #714692) in Combination With Carboplatin (NSC #241240)” NCT00086892 ↗

“Carboplatin (Paraplatin, NSC #241240)” NCT00112489 ↗

Known as Paraplatin “The purpose of this study is to determine the effectiveness of the combination of the two drugs, docetaxel (Taxotere®) and carboplatin (Paraplatin®) followed by radiation...” NCT00285415 ↗
15

“This study was designed to find the safest and most effective dose of a combination of two chemotherapy drugs, Hycamtin® (topotecan) and Paraplatin® (carboplatin), in people...” NCT00316186 ↗

“Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or...” NCT00687687 ↗

“A Randomized Phase III Trial of Paraplatin (Carboplatin) + Gemzar Versus Gemzar Alone in Patients With Advanced Non Small Cell Lung Cancer” NCT00190710 ↗

“The two drug combination, carboplatin (Paraplatin) and paclitaxel (Taxol), is commonly used as the first treatment.” NCT00161278 ↗

“The product label for (Paraplatin) carboplatin Injection provides the following dosing information.” NCT03149575 ↗

“Carboplatin (Paraplatin®) 100 mg IV administered over 30 minutes at the start of craniotomy” NCT02279992 ↗

“Phase II Trial of Gemcitabine/Paraplatin® (Carboplatin) Followed by Taxol® (Paclitaxel)” NCT00276588 ↗

“Taxol(Paclitaxel) and Carboplatin(Paraplatin) Regimen” NCT00035152 ↗

“Carboplatin (Paraplatin, NSC #241240)” NCT00112489 ↗

“Carboplatin (Paraplatin®)” NCT00130936 ↗

Show 5 more sources

Known as Paraplatin (Carboplatin) “Paraplatin (Carboplatin)” NCT05948462 ↗
2

“Paraplatin (Carboplatin)” NCT00249964 ↗

“Paraplatin (carboplatin)” NCT01653912 ↗